Problem
Triple Negative Breast Cancer (TNBC) constitutes 15 – 20% of all breast cancers. It is highly aggressive, relapsing within 3 – 5 years of chemotherapy in young women. Therapeutic progress in TNBC has been limited to chemotherapy in the past several decades. There is therefore a need for the development of targeted therapeutics with increased selectivity and efficacy and decreased toxicity for the treatment of those suffering from TNBC.

Solution
This is a targeted TNBC therapy formed of an antineoplastic agent and an LHRH (Leuteinising hormone release hormone) peptide derivative which has been conjugated to an anti-mitotic agent. This therapeutic drug targets LHRH receptors, which are overexpressed in 70-100% TNBCs. The targeting and anti-mitotic agent combination will efficiently identify the target cells/tumours and prevent mitosis of the cancerous cells.

Commercial Opportunity
An entirely new class of cancer drugs with a demonstrated efficacy in targeting Triple Negative Breast Cancer (TNBC) may be acquired.

Potential Commercial Applications
– Sole therapy in the treatment of TNBC
– Therapy for multiple cancer types that overexpress LHRH.

Inventors
Pegah Varamini and Sepideh Khazeni.

Contact Commercialisation Office
Name: Julius Juarez
Position: Commercialisation Manager
Email: julius.juarez@sydney.edu.au | Phone: +61 403 181 295
sydney.edu.au/innovation-and-enterprise